A Study to Compare the Relative Bioavailability of Brigatinib When Swallowed as a Solution Versus When Swallowed as a Tablet in Healthy Adults

Cmax: Maximum Observed Plasma Concentration for Brigatinib [Time Frame: Predose at Day 1 and multiple times (up to 168 hours) post dose up to Day 8 of Period 1 and Period 2 (Each Period length= 8 days)]

AUClast: Area Under the Plasma Concentration-Time Curve from Time 0 to the Time of the Last Quantifiable Concentration for Brigatinib [Time Frame: Predose at Day 1 and multiple times (up to 168 hours) post dose up to Day 8 of Period 1 and Period 2 (Each Period length= 8 days)]

AUC∞: Area Under the Plasma Concentration-Time Curve from Time 0 to Infinity for Brigatinib [Time Frame: Predose at Day 1 and multiple times (up to 168 hours) post dose up to Day 8 of Period 1 and Period 2 (Each Period length= 8 days)]

Number of Participants with at Least One Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) [Time Frame: From signing of informed consent to 14 (±2) days after last dose (up to 56 days)]